期刊文献+

尼美舒利分散片在健康人体内的药代动力学及生物等效性的LC-MS/MS研究 被引量:6

Clinical pharmacokinetics and bioequivalence of nimesulide dispersible tablets by LC-MS/MS method
原文传递
导出
摘要 目的:建立人血浆中尼美舒利浓度的LC-MS/MS测定法,并用于尼美舒利分散片的药代动力学和生物等效性研究。方法:采用自身双交叉试验设计,20名男性受试者随机分成2组,分别单剂量口服100 mg受试制剂或参比制剂,0~24 h间隔采集血样。以LC-MS/MS内标法测定尼美舒利血药浓度,使用Agilent TC-C18色谱柱(250 mm×4.6 mm,5μm),流动相为甲醇-0.1%甲酸溶液(82∶18,v/v);多反应监测[M+H]+离子通道分别为m/z 309.1→m/z 153.9(尼美舒利)和m/z 237.1→m/z 194.0(内标卡马西平),DAS 2.1计算药动学参数。结果:建立的LC-MS/MS法在0.075~12μg·mL-1范围内色谱响应与浓度相关性良好,最低定量限为0.075μg·mL-1,批内及批间精密度RSD均小于15%。受试制剂与参比制剂的Tmax分别为(3.0±0.7)h和(3.5±1.0)h,Cmax分别为(4.863±1.194)μg·mL-1和(4.657±1.038)μg·mL-1,t1/2分别为(3.2±1.0)h和(3.3±1.1)h,AUC0-24 h分别为(32.35±12.50)h·μg·mL-1和(32.32±11.69)h·μg·mL-1,相对生物利用度F为(105.2%±35.0)%。结论:建立的LC-MS/MS法准确、灵敏,结果可靠,测得尼美舒利受试制剂和参比制剂生物等效。 Objective:To establish an LC -MS/MS method for the determination of nimesulide in human plasma, used for the study of the clinical pharmocokinetics and bioequivalence of nimesulide dispersible tablets. Methods: In a randomized two -way self- crossover study ,20 healthy male volunteers were divided into two groups, and were administered respectively either with a single oral dose of test or reference preparations containing 100 mg of nime- sulide. The blood samples were collected at predetermined time intervals within 24 hours. The plasma concentration of nimesulide was determined by LC - MS/MS. The chromatographic separation was performed on an Agilent TC - C18 (250 mm × 4.6 mm,5 μm) column with a mobile phase consisting of methanol and water solvent with 0.1% formic acid( 82:18 ,v/v). The analytes were detected by multiple reaction monitoring of the [ M ± H ] ± ions with transi- tions of m/z 309.1→m/z 153.9 and m/z 237.1→m/z 194.0 for nimesulide and carbamazepine, respectively. The pharmacokinetic parameters were estimated by DAS 2.1. Results:The peak areas and concentrations showed good correlation in the range of 0. 075 -12 μg . mL-1 with a LOQ of 0. 075 μg . mL-1 for quantitation of nimesulide in human plasma. The intra- and inter- batch precision RSDs were less than 15%. The pharmacokinetie parameters of the test and reference tablets were as follows : T_max ( 3.0 ± 0.7 ) and ( 3.5 ± 1.0 ) h, C (4. 863 ± 1. 194 ) and (4. 657±1.038 ) μg . mL - 1 , t 1/2 ( 3. 2± 1. 0 ) and ( 3.3 ± 1.1 ) h, AUC0-24 h ( 32. 35 ± 12. 50 ) and ( 32.32 ± 11.69 ) h .μg .mL- 1, respectively. The relative bioavailability F was ( 105.2% ± 35.0 ) %. Conclusion: The method is ac-curate, sensitive, reliable and suitable for the pharmacokinetic study of nimesulide. The two preparations are bio- equivalent.
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第1期30-33,38,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 尼美舒利 环氧化酶-2抑制剂 分散片 血药浓度 药动学 生物等效性 液相色谱-串联质谱法 nimesulide cox - 2 inhibitor dispersible tablet plasma drug concentration pharmacokinetics bioequiv-alence LC - MS/MS
  • 相关文献

参考文献6

二级参考文献35

共引文献13

同被引文献41

  • 1Barrientos Asrigarraga RE, Vannuchi YB, Sucupira M, et al. Quan- tification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry, Application to bioequiva- lence studies [J]. Mass Spectrom,2001,36(12) :1281-1284.
  • 2FDA. BioavailaMlity and bioequivalence requirements: Defini- tions[ EB/OL]. Code of Federal Regulation Title 21 (CFR 21 ) Sec. 320.1,(2014-04-01) [2014 -08-13]. http://www. accessdata, fda. gov/scripts/cdrh/efdocs/cfCFR/CFRSearch, cfm? fr =320.1.
  • 3DICKINSON PA, LEE WW, STOTT PW, et al. Clinical rele- vance of dissolution testing in quality by design [ J]. AAPS J, 2008, 10(2) :3,0 -390.
  • 4AMIDON GE, HAWLEY M. Oral bioperformance and 21st cen- tury dissolution[ J]. Mol Pharm, 2010, 7 (5) : 1388 - 1405.
  • 5US Department ,ff Health and Human Services, Food and Drug Administration Eenter for Drug Evaluation and Research (CDER) , Guidance for industry. Waiver of in vivo Bioavailabili- ty and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Bused on a Biopharmaceutics Classification System IS]. August 2000.
  • 6POLLI JE. In viro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequiva- lence of immediate-release solid oral dosage forms[ J]. AAPS J, 2008, 10(2) : 289 -299.
  • 7FIP. The biowaier monographs-what have we learned? [ EB/OL ]. Biowaiver monographs 2004 - 2012, [ 2014 - 09 - 04 ]. http :// www. fip. org/publieations.
  • 8GRAHAM GG, PUNT J, ARORA M, et al. Clinical pharmaco-kinetics of metformin [ J ]. Clln Pharmacokinet, 2011, 50 ( 2 ) : 81 -gg.
  • 9CHENG CL, YU LX, LEE HL, et al. Biowaiver extension po- tential to BCS Class II1 high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet [ J ]. Eur J Pharm Sci, 2004, 22(4): 297-304.
  • 10SAMBOL NC, BROOKES LG, CHIANG J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HC1 in man[ J]. Br J Clin Pharma- col, 1996, 42(4) :510 -512.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部